Protalix BioTherapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Protalix BioTherapeutics has a total shareholder equity of $33.6M and total debt of $20.3M, which brings its debt-to-equity ratio to 60.3%. Its total assets and total liabilities are $84.4M and $50.9M respectively. Protalix BioTherapeutics's EBIT is $10.5M making its interest coverage ratio 5.5. It has cash and short-term investments of $44.6M.
Key information
60.3%
Debt to equity ratio
US$20.25m
Debt
| Interest coverage ratio | 5.5x |
| Cash | US$44.56m |
| Equity | US$33.57m |
| Total liabilities | US$50.87m |
| Total assets | US$84.43m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: PLX's short term assets ($69.9M) exceed its short term liabilities ($45.5M).
Long Term Liabilities: PLX's short term assets ($69.9M) exceed its long term liabilities ($5.3M).
Debt to Equity History and Analysis
Debt Level: PLX has more cash than its total debt.
Reducing Debt: PLX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: PLX's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: PLX's interest payments on its debt are well covered by EBIT (5.5x coverage).